Global Vaccine Contract Manufacturing Market Poised to Reach USD 7.04 Billion by 2031, Growing at a CAGR of 12.45%
Straits Research: Revolutionizing Vaccine Production Through Strategic Partnerships
The global vaccine contract manufacturing market has been experiencing remarkable growth, with its market size valued at USD 2.45 billion in 2022. Straits Research projects this market to expand significantly, reaching USD 7.04 billion by 2031, at a compound annual growth rate (CAGR) of 12.45% from 2023 to 2031.
For a comprehensive overview of the market, download the full PDF sample report here: https://straitsresearch.com/report/vaccine-contract-manufacturing-market/request-sample
Market Definition
Vaccine contract manufacturing refers to outsourcing vaccine production to specialized firms with the technical expertise, infrastructure, and regulatory compliance capabilities. This model allows pharmaceutical companies to focus on core competencies such as R&D while leveraging the manufacturing capabilities of contract service providers.
Market Dynamics
Key Trends
- Rise in mRNA Vaccine Development: The success of mRNA-based vaccines during the COVID-19 pandemic has spurred a wave of innovation and investments in this domain, driving demand for specialized manufacturing services.
- Adoption of Single-Use Technologies: The industry is increasingly adopting single-use systems to reduce contamination risks and enhance production efficiency.
Market Drivers
- Growing Vaccine Demand: Rising prevalence of infectious diseases and an increased focus on immunization programs globally are fueling the demand for vaccines.
- Advancements in Biomanufacturing: Innovations in cell culture technologies, bioreactors, and downstream processing are enabling efficient and scalable vaccine production.
Market Opportunities
- Emerging Markets: Developing economies present untapped opportunities due to increasing healthcare investments and vaccine accessibility programs.
- Partnerships and Collaborations: Strategic alliances between pharmaceutical companies and contract manufacturers are paving the way for market expansion.
Market Segmentation
The vaccine contract manufacturing market is segmented as follows:
By Scale of Operation:
- Commercial
- Clinical
- Preclinical
By Vaccine Type:
- Sub-attenuated Vaccines
- Live-attenuated Vaccines
- Inactivated Vaccines
- Others
By Service:
- Fill/Finish
- Analytical and QC Studies
- Cell/Virus Banking
- Others
Access detailed segmentation here: https://straitsresearch.com/report/vaccine-contract-manufacturing-market/segmentation
Key Market Players
Prominent players driving the vaccine contract manufacturing market include:
- Ajinomoto
- Albany Molecular Research
- Catalent
- Cytovance Biologics
- Emergent BioSolutions
- FUJIFILM Diosynth Biotechnologies
- GSK
- ICON
- IDT Biologika
- Lonza
- Merck KGaA
- Pfizer CentreOne
- Recipharm
- Siegfried
Regional Insights
- Dominated Region: North America holds the lion's share of the vaccine contract manufacturing market, driven by advanced healthcare infrastructure and robust R&D investments.
- Fastest Growing Region: Europe is projected to witness the highest growth rate, fueled by increasing government initiatives and technological advancements in biomanufacturing.
For more information, queries, or customization before purchasing the report, visit: https://straitsresearch.com/buy-now/vaccine-contract-manufacturing-market
About Straits Research
Straits Research is dedicated to providing businesses with the highest quality market research services. With a team of experienced researchers and analysts, we strive to deliver insightful and actionable data that helps our clients make informed decisions about their industry and market. Our customized approach allows us to tailor our research to each client's specific needs and goals, ensuring that they receive the most relevant and valuable insights.
Contact Us
Email: sales@straitsresearch.com
Address: 825 3rd Avenue, New York, NY, USA, 10022
Tel: UK: +44 203 695 0070, USA: +1 646 905 0080
